Answers are grounded in this paper and cite their sources.
Fibrotic interstitial lung diseases (ILDs) differ in their likelihood and rate of progression. This narrative review examines persistent injury, failed alveolar repair and feedback that sustains fibrosis, then relates these processes to clinical decisions. Causal mechanistic evidence comes mainly from mouse experiments and cell models; human tissue studies, often in advanced idiopathic pulmonary fibrosis (IPF), establish disease relevance but rarely the temporal sequence. Comparable mechanisms in hypersensitivity pneumonitis, autoimmune ILD and treatment-related injury require disease-specific validation. We assess susceptibility, progression after diagnosis and treatment benefit as separate questions. Genetic and telomere findings can inform counselling or treatment safety, whereas antigen investigation and avoidance address a potential source of ongoing injury. Imaging, bronchoalveolar lavage and systemic inflammatory activity can inform assessment in selected non-IPF diseases, but no validated rule uses these features to choose immunosuppression over antifibrotic therapy. Randomized trials support treatment in defined IPF, autoimmune ILD and progressive pulmonary fibrosis populations, principally through effects on lung function. Unsuccessful integrin-targeting trials also show that pathway plausibility does not establish clinical benefit or safety. Clinical action should therefore follow the underlying diagnosis, documented course and treatment indication, with explicit attention to toxicity and the outcome actually studied.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: